Soligenix Secures $7.5 Million Financing to Advance Rare Disease Pipeline Through 2026
Soligenix has closed a $7.5 million public offering that extends its financial runway through 2026, providing critical funding to advance multiple late-stage rare disease treatments including its cutaneous T-cell lymphoma therapy HyBryte™.
Soligenix Inc. has completed a $7.5 million public offering that significantly extends the company's financial runway through the end of 2026, providing essential capital to advance its pipeline of rare disease treatments. The financing involved the sale of 5,555,560 shares of common stock and accompanying warrants at $1.35 per share, with participation from both existing and institutional healthcare investors.
The capital infusion comes at a critical time for the late-stage biopharmaceutical company as it advances multiple therapeutic candidates toward potential commercialization. The proceeds are designated to fund research and development activities, commercialization efforts, working capital requirements, and general corporate purposes. The offering also included amendments to prior warrants, adjusting their exercise price to $1.35 to align with current market conditions.
This financial stability through 2026 provides Soligenix with the necessary runway to advance its lead candidate, HyBryte™ (SGX301), through the regulatory approval process. The synthetic hypericin sodium treatment represents a novel photodynamic therapy utilizing safe visible light for cutaneous T-cell lymphoma, having successfully completed its second Phase 3 study. The company plans to seek regulatory approvals worldwide to support potential commercialization of this rare disease treatment.
Beyond its CTCL program, Soligenix's development pipeline includes multiple promising candidates. The company is expanding synthetic hypericin (SGX302) into psoriasis treatment and advancing its first-in-class innate defense regulator technology, dusquetide (SGX942), for inflammatory diseases including oral mucositis in head and neck cancer patients. Additional development includes SGX945 for Behcet's Disease, addressing significant unmet medical needs across multiple rare conditions.
The company's Public Health Solutions business segment continues to advance vaccine candidates with government support. This includes RiVax® for ricin toxin protection, filovirus vaccines targeting Marburg and Ebola viruses, and CiVax™ for COVID-19 prevention. These programs incorporate the company's proprietary ThermoVax® heat stabilization platform technology and have received funding from multiple government agencies including the National Institute of Allergy and Infectious Diseases, the Defense Threat Reduction Agency, and the Biomedical Advanced Research and Development Authority. Additional information about Soligenix's developments is available in the company's newsroom at https://ibn.fm/SNGX.
The successful financing demonstrates investor confidence in Soligenix's strategic direction and pipeline potential during a challenging period for biotech funding. The extended cash runway through 2026 provides the company with operational stability to navigate the complex regulatory landscape for rare disease treatments while advancing multiple clinical programs simultaneously. This financial foundation positions Soligenix to potentially bring novel therapies to patients suffering from rare diseases with limited treatment options.